News

Conference Coverage

Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer

01/20/2024

Allison Casey

According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...

According to updated results...

01/20/2024

Oncology

Conference Coverage

Combining Clinical Biomarkers for Optimal Selection of First-Line Treatment in Metastatic Colorectal Cancer

01/20/2024

Allison Casey

According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.

According to results from the...

01/20/2024

Oncology

Conference Coverage

Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer

01/20/2024

Allison Casey

In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.

In the phase 2/3 COBRA study no...

01/20/2024

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Featuring Sara Lonardi, MD

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

News

FDA Grants Approval to Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer

11/10/2023

Allison Casey

On November 8, 2023, the FDA approved fruquintinib for the treatment of patients with metastatic colorectal cancer who had previously been treated with multiple chemotherapies, an anti-VEGF therapy, and, if necessary, an anti-EGFR therapy.

On November 8, 2023, the FDA...

11/10/2023

Oncology

Filippo Pietrantonio, MD, National Cancer Center Milan

Videos

Sotorasib Plus Panitumumab Improved PFS Among Patients With Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer

11/07/2023

Featuring Filippo Pietrantonio, MD

Featuring Filippo Pietrantonio, MD ...

Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...

Primary results from the phase 3...

11/07/2023

Oncology

Shinichi Nishina, MD, Kurashiki Central Hospital

Videos

RAS Status in ctDNA After Chemotherapy Among Patients With RAS-Mutant Colorectal Cancer

08/28/2023

Featuring Shinichi Nishina, MD

Featuring Shinichi Nishina, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Shinichi Nishina, MD, reported data on that RAS status in ctDNA of patients with RAS-mutant metastatic colorectal cancer who responded to first- or second-line chemotherapy.

At the 2023 World Congress on...

08/28/2023

Oncology

Videos

Increasing Incidence of Early-Onset Colorectal Cancer

08/28/2023

Featuring Irit Ben-Aharon, MD, PhD

Featuring Irit Ben-Aharon, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Irit Ben-Aharon, MD, PhD discussed how the incidence of early-onset colorectal cancer has risen over the past 2 decades.

At the 2023 World Congress on...

08/28/2023

Oncology

Josep Tabernero, MD, PhD, Vall d'Hebron Barcelona Hospital Campus

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Featuring Josep Tabernero, MD, PhD

Featuring Josep Tabernero, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

Thierry André, MD, Saint-Antoine Hospital

Videos

Integrating Checkpoint Inhibitors into Treatment of Patients MSI-High Rectal Cancer

08/24/2023

Featuring Thierry André, MD

At the 2023 World Congress on Gastrointestinal Cancers, Thierry André, MD, discussed the use of checkpoint inhibitors for patients with MSI-high colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology